“To Accelerate Access to Asthma Medicine”: AstraZeneca Pharma India Limited Partners with Mankind Pharma Limited

An exclusive distribution deal was signed by AstraZeneca Pharma India Limited and Mankind Pharma Limited for AstraZeneca's Symbicort brand, which is an inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination of budesonide and formoterol fumarate dihydrate. AstraZeneca will continue to hold the import license and Marketing Authorization Holder (MAH) for budesonide and formoterol fumarate dihydrate, as well as the intellectual property rights to these medications.

India accounts for a disproportionate 43% of the world's asthma mortality and 13% of the burden of asthma worldwide. It becomes evident how much room there is for improvement in the nation's asthma management system.

“The collaboration with Mankind Pharma offers a chance to boost accessibility and optimize the efficacy of our asthma medication in addition to the turbuhaler, a low-tech tool that reliably delivers a greater percentage of respirable particles than competing products. We are as eager to quickly provide cutting-edge medicine to India as we are committed to strategically enhancing access in the nation," stated Dr. Sanjeev Panchal, Managing Director and Country President of AstraZeneca India.

Atish Majumdar, Senior President of Sales and Marketing at Mankind Pharma Limited, made comments regarding the arrangement with AstraZeneca India , “We are thrilled to collaborate with AstraZeneca to elevate their cutting-edge flagship brand Symbicort to a standard of care for asthma around the world. Patients can significantly enhance their quality of life and manage these illnesses with the help of Symbicort's dual mechanism of action and single inhaler ease of use. Using the broad outreach of our field troops, we aim to enhance accessibility in both urban and rural markets. We both want to improve patient outcomes, so I think this partnership is strategic in a lot of ways. Such reputable collaborations, in our opinion, that increase the availability of internationally recognized medications in India perfectly capture our philosophy of prioritizing patients while maintaining value.”